Shangyao Shandong won 70% of the shares of Luoxin Modern Logistics! Stripping, selling, transferring, what do pharmaceutical companies want to do?

No matter in what form of "slimming", for pharmaceutical companies, the purpose is to be able to better focus on the main business, transformation and upgrading
.

On September 21, Shanghai Pharmaceutical Holdings and Luoxin Pharmaceutical held a signing ceremony
for investment and strategic cooperation agreement.

Source: Listed Company Announcements

Divestiture of non-core business has always been a routine move of multinational pharmaceutical companies, but in recent years, this is no longer an "exclusive action"
of multinational pharmaceutical companies.

"Win-win" deals

In the announcement, Shanghai Pharmaceutical Holdings said that the two sides will jointly explore more novel and practical cooperation models
in the fields of pre-market services for innovative drugs, national market access, and national collection.

For the goal of this cooperation, Shanghai Pharmaceutical said that "in the field of pharmaceutical circulation, the two sides take equity cooperation as the link, gather their outstanding advantages in pharmaceutical circulation, import, manufacturing and supply chain services, and will focus on consolidating the network layout and deepening the terminal market
in Shandong region.

In July this year, in the seventh batch of collection, Luoxin's Edarabon injection, cefamezole sodium for injection and meropenem for injection won the bid for the centralized procurement
of drugs nationwide.

In addition to Taixinzan, Luoxin also has two self-developed Class 1 new drugs - LX-039 and LX-086 have also entered the clinical trial stage, which are used for the treatment of advanced solid tumors and the treatment
of ER-positive advanced breast cancer.

In recent years, Shanghai Pharmaceutical has also been continuously optimizing and expanding its commercial business
.

In the semi-annual report, Shanghai Pharmaceutical has said that Shanghai Pharmaceutical adheres to transformation and development, and continues to promote the development strategy
of "innovation, intensification, internationalization and combination of finance and industry".

Focus on the main business "each has its own advantages"

On June 14, 2020, Tasly announced that it intends to sell the assets of the distribution and distribution business under the company's pharmaceutical business operation model for 1.

Tiansheng Pharmaceutical said: The transaction divested the pharmaceutical circulation business, further adjusted the business structure, and formed an overall business arrangement
that is more in line with the company's strategic development.

In July, Sihuan Pharmaceutical announced that it will adjust its business model to gradually complete the potential sale in the next 12-24 months, divesting and selling some generic drugs, other non-core pharmaceutical and big health business assets that have not met business expectations and are not in line with long-term strategic development goals, and have now sold Beijing Xuansheng Pharmaceutical Company
, which has potential similar competition and generated a net loss, for 118 million.

At the same time, the announcement pointed out that the company will focus its management on the more growing business segments
.

This not optimistic semi-annual report shows that the medical beauty project has not become the "gripper" of the performance growth of Sihuan Pharmaceutical, and the innovative drug business that has been laid out for more than ten years has generated 0
revenue.

Before the official release of the semi-annual report, Tonghua Toho issued performance forecasts
twice.

At the same time
.

But at the same time, there are also enterprises
like Yan'an Bikang that focus on "making money" in the divestiture of the pharmaceutical sector.
At the end of last year, Yan'an Bikang issued an announcement that in order to gradually divest the pharmaceutical business, further improve and adjust the company's industrial and investment structure, and focus more on the development of new energy and new materials industry, the leader who once had tens of billions of yuan in revenue announced his withdrawal from the pharmaceutical industry
.
Once focused on the scale of local pharmaceutical companies have begun to put down the "idol baggage", no matter in what form of "slimming", for pharmaceutical companies, the purpose is to be able to better focus on the main business, transformation and upgrading, under the influence of policies such as collection, there may be more companies in the future to give up commercial circulation, generic drugs and other businesses, light
loading.